{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:51:08Z","timestamp":1792144268574,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.4065\/mcp.2009.0700","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T17:33:16Z","timestamp":1275067996000},"page":"512-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study"],"prefix":"10.4065","volume":"85","author":[{"given":"Richard K.","family":"Bogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A. Cramer","family":"Bornemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clete A.","family":"Kushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre V.","family":"Tr\u00e2n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.4065\/mcp.2009.0700_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"issue":"11","key":"10.4065\/mcp.2009.0700_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.4065\/mcp.2009.0700_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"issue":"5","key":"10.4065\/mcp.2009.0700_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.sleep.2004.04.004","article-title":"Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS","volume":"5","author":"Kushida","year":"2004","journal-title":"Sleep Med"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4065\/81.1.17","article-title":"Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial","volume":"81","author":"Bogan","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/mcp.2009.0700_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.4065\/mcp.2009.0700_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.sleep.2008.09.001","article-title":"Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Ferini-Strambi","year":"2008","journal-title":"Sleep Med"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib9","first-page":"92","article-title":"Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries","volume":"75","author":"Trenkwalder","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.4065\/mcp.2009.0700_bib10","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.20257","article-title":"Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study","volume":"19","author":"Walters","year":"2004","journal-title":"Mov Disord"},{"issue":"6","key":"10.4065\/mcp.2009.0700_bib11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/01.wnl.0000231513.23919.a1","article-title":"Efficacy and safety of pramipexole in restless legs syndrome","volume":"67","author":"Winkelman","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.4065\/mcp.2009.0700_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.4065\/mcp.2009.0700_bib13","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.57.9.1717","article-title":"Treatment of idiopathic restless legs syndrome (RLS) with gabapentin","volume":"57","author":"Happe","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000072882","article-title":"Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome","volume":"48","author":"Happe","year":"2003","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","article-title":"Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy","volume":"31","author":"Gidal","year":"1998","journal-title":"Epilepsy Res"},{"issue":"2-3","key":"10.4065\/mcp.2009.0700_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.4065\/mcp.2009.0700_bib17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1528-1157.1997.tb01223.x","article-title":"Failure of absorption of gabapentin after rectal administration","volume":"38","author":"Kriel","year":"1997","journal-title":"Epilepsia"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1157.1997.tb01078.x","article-title":"Colonic absorption of antiepileptic agents","volume":"38","author":"Stevenson","year":"1997","journal-title":"Epilepsia"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1528-1157.1998.tb01357.x","article-title":"Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy","volume":"39","author":"Beydoun","year":"1998","journal-title":"Epilepsia"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(+\/\u2212)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II, improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.4065\/mcp.2009.0700_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 [(+\/\u2212)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I, design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.4065\/mcp.2009.0700_bib23","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.4065\/mcp.2009.0700_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"A randomized, double-blind, placebo-controlled trial of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1389-9457(03)00009-1","article-title":"Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures","volume":"4","author":"Hening","year":"2003","journal-title":"Sleep Med"},{"key":"10.4065\/mcp.2009.0700_bib26","author":"World Medical Association"},{"key":"10.4065\/mcp.2009.0700_bib27","series-title":"Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.4065\/mcp.2009.0700_bib28","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"218","article-title":"Early clinical drug evaluation unit (ECDEU). clinical global impressions","author":"National Institute of Mental Health (NIMH)","year":"1976"},{"issue":"5","key":"10.4065\/mcp.2009.0700_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","article-title":"Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep)","volume":"10","author":"Allen","year":"2008","journal-title":"Sleep Med"},{"key":"10.4065\/mcp.2009.0700_bib30","series-title":"Measuring Functioning and Well-being: The Medical Outcomes Study Approach","first-page":"235","article-title":"Sleep measures","author":"Hays","year":"1992"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1524-4733.2005.03010.x","article-title":"Validation of the Restless Legs Syndrome Quality of Life questionnaire","volume":"8","author":"Abetz","year":"2005","journal-title":"Value Health"},{"issue":"10","key":"10.4065\/mcp.2009.0700_bib32","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.21050","article-title":"Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial","volume":"21","author":"Montplaisir","year":"2006","journal-title":"Mov Disord"},{"issue":"9","key":"10.4065\/mcp.2009.0700_bib33","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.20983","article-title":"Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome","volume":"21","author":"Trenkwalder","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.43.2.445","article-title":"Dopaminergic treatment of restless legs and rebound phenomenon","volume":"43","author":"Guilleminault","year":"1993","journal-title":"Neurology"},{"issue":"7651","key":"10.4065\/mcp.2009.0700_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.4065\/mcp.2009.0700_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","article-title":"A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome","volume":"32","author":"Kushida","year":"2009","journal-title":"Sleep"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:41:11Z","timestamp":1706002871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611603418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0025619611603418"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2009.0700","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2009.0700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0267","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}